Propranolol in Primary Progressive Aphasia

University of Missouri-Columbia (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure.

This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Study Design

Study Type:
Anticipated Enrollment :
20 participants
Intervention Model:
Crossover Assignment
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Official Title:
Trial of Propranolol in Older Adults With Primary Progressive Aphasia
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2026
Anticipated Study Completion Date :
Oct 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Propanolol and MRI

Participants will receive propranolol via oral capsule. The drug dosage will be titrated slowly to ensure the drug is tolerated well.

Drug: Propranolol
Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.

Device: Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.

Placebo Comparator: Placebo and MRI

Participants will receive placebo via oral capsule.

Device: Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.

Drug: Placebo
Placebo will be given on the same schedule as the propranolol regime.

Outcome Measures

Primary Outcome Measures

  1. Change in Neuropsychological Assessment Battery Naming Test [Day 1, 4 Weeks, 8 Weeks, 10 Weeks, 14 Weeks,18 Weeks]

Secondary Outcome Measures

  1. Change in State-Trait Anxiety Inventory for Adults [Day 1, 4 Weeks, 8 Weeks, 10 Weeks,14 Weeks,18 Weeks]

    The State-Trait Anxiety scores range from 20-40. A higher score indicates more anxiety.

  2. Change in Semantic Word Fluency Tasks [Day 1, 8 Weeks,18 Weeks]

    The Semantic Word Fluency task measures the subject's ability to name as many items in a minute in a given category. The total number of correct and non-repeated responses are totaled for each category. There is no minimum or maximum score. Higher scores indicate better word fluency.

Eligibility Criteria


Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
    1. Age: 50 and older
    1. Primary Progressive Aphasia diagnosis
    1. Native English speaker
Exclusion Criteria:
    1. Unable to provide consent
    1. Taking alpha 2 agonists (clonidine and guanfacine)
    1. Other major psychological or neurological diagnosis
    1. Major head trauma that contributed to their condition
    1. Allergic reaction to adhesives
    1. Uncorrected vision/hearing impairments
    1. Diabetes
    1. Reactive airway disease
    1. Untreated hypothyroidism
    1. Bradyarrhythmia
    1. Unexplained syncope
    1. Pregnancy (assessed verbally on the days of MR imaging)
    1. Drugs that interact with propranolol, such as alpha 2 agonists
    1. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.

Contacts and Locations


Site City State Country Postal Code
1 University of Missouri-Columbia Columbia Missouri United States 65212

Sponsors and Collaborators

  • University of Missouri-Columbia


  • Principal Investigator: David Beversdorf, MD, University of Missouri-Columbia

Study Documents (Full-Text)

None provided.

More Information


Responsible Party:
David Beversdorf, Professor, Department of Radiology & Thompson Center for Autism & Neurodevelopmental Disorders, University of Missouri-Columbia, University of Missouri-Columbia Identifier:
Other Study ID Numbers:
  • 2097152
First Posted:
Oct 4, 2023
Last Update Posted:
Oct 4, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 4, 2023